AZD6234
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel
AstraZeneca · Phase 1 · Active, not recruiting · Enrollment 100
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Cohort-1: AZD6234 + EE/LEVO + Acetaminophen (APAP) | n/r | n/r | n/r | n/r |
| Cohort-2: AZD6234+AZD9550+EE/LEVO+APAP | n/r | n/r | n/r | n/r |
| Cohort-3: AZD9550 + EE/LEVO + APAP | n/r | n/r | n/r | n/r |
| Cohort-4: AZD6234+AZD9550+EE/LEVO+APAP | n/r | n/r | n/r | n/r |
Not shown
- Cohort-1: AZD6234 + EE/LEVO + Acetaminophen (APAP): endpoint not reported
- Cohort-2: AZD6234+AZD9550+EE/LEVO+APAP: endpoint not reported
- Cohort-3: AZD9550 + EE/LEVO + APAP: endpoint not reported
- Cohort-4: AZD6234+AZD9550+EE/LEVO+APAP: endpoint not reported